Brookdale Senior Living Inc. (BKD) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Brookdale Senior Living Inc. (NYSE: BKD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $10.39 (+1.17% 1D, market cap $2.45B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BKD ranks #797 in composite RQD confidence.
Within the Health Care sector (Hospital/Nursing Management), BKD carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 26.2%, and ROIC of 0.3%. By comparison, MD (Pediatrix Medical Group Inc.) holds a B+ grade (76/100 RQD, P/E 14.3x, ROIC 33.6%, cap $2.37B) and SGRY (Surgery Partners Inc.) posts a C+ grade (66/100 RQD, P/E N/A, ROIC 9.9%, cap $3.04B). Among the 5-stock peer group, ARDT leads on earnings multiple (12.8x) while MD leads on capital efficiency (33.6% ROIC).
Per BKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001332349), Brookdale Senior Living Inc. generated $3.19B in revenue (+2.2% YoY), -$262.7M in net income, and $16.5M in free cash flow against $5.95B in total assets and $4.22B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($16.5M FCF) & 26.2% Gross Margin
20D Institutional Volume Accumulation (±7.1% realized swing band)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While BKD currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.03) and Max Pain ($10.91) forces dealer call-delta covering toward $17.94.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Brookdale Senior Living Inc. (BKD) advanced +1.17% to $10.39, trading at 26% of its 52-week range ($8.02 – $17.09). Stretched risk/reward at current multiples (0% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
PR Newswire report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
StockStory report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
October jobs report: election and inflation risks, sector winners, and top stock picks in health care, finance, manufacturing, and defense.
Antipodes Partners published its third-quarter 2026 investor letter for “Antipodes Global Fund.” The letter can be downloaded here. In Q3 2026, markets were volatile but broadly positive, with global equities rising 1.6%
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +2.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BKD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BKD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Brookdale Senior Living Inc. (BKD) ranks #797 by composite RQD confidence (31/100, grade E) and #223 by equity capitalization ($2.45B). Within this direct 5-issuer industry benchmark cohort, ARDT leads on earnings valuation at 12.8x trailing P/E, while MD leads on capital efficiency and profitability with 33.6% ROIC and — gross margin. MD currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with BKD at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BKD
ACTIVE
Brookdale Senior Living Inc. | E | 31/100 | — | 26.2% | 0.3% | +1.17% | $2.45B | Benchmark Subject |
| MD Pediatrix Medical Group Inc. | B+ | 76/100 | 14.3x | — | 33.6% | +2.19% | $2.37B | /md-vs-bkd → |
| SGRY Surgery Partners Inc. | C+ | 66/100 | — | — | 9.9% | 0.00% | $3.04B | /sgry-vs-bkd → |
| NHC National HealthCare Corporation | B | 73/100 | 27.7x | — | 10.1% | -2.84% | $3.32B | /nhc-vs-bkd → |
| ARDT Ardent Health Inc. | C+ | 69/100 | 12.8x | — | 10.5% | -2.19% | $1.73B | /ardt-vs-bkd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Brookdale Senior Living Inc. (BKD) reported GAAP revenue of $3.19B (+2.2% vs. FY2024 revenue of $3.13B , and +5.9% cumulative change since FY2023) , GAAP net income of -$262.7M, operating cash flow of $218.0M, and free cash flow of $16.5M (+147.1% YoY). On the balance sheet, BKD closed FY2025 with $5.95B in total assets against $4.22B in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.19B | -$262.7M | $218.0M | $16.5M | $5.95B | $4.22B |
| FY2024 (FY) | 2024-12-31 | $3.13B | -$201.9M | $166.2M | -$35.1M | $6.34B | $4.02B |
| FY2023 (FY) | 2023-12-31 | $3.02B | -$189.0M | $162.9M | $162.9M | — | — |
As of 2026-11-02, Brookdale Senior Living Inc. (NYSE: BKD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $10.39 (+1.17% 1D, market cap $2.45B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BKD ranks #797 in composite RQD confidence.
Within the Health Care sector (Hospital/Nursing Management), BKD carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 26.2%, and ROIC of 0.3%. By comparison, MD (Pediatrix Medical Group Inc.) holds a B+ grade (76/100 RQD, P/E 14.3x, ROIC 33.6%, cap $2.37B) and SGRY (Surgery Partners Inc.) posts a C+ grade (66/100 RQD, P/E N/A, ROIC 9.9%, cap $3.04B). Among the 5-stock peer group, ARDT leads on earnings multiple (12.8x) while MD leads on capital efficiency (33.6% ROIC).
Per BKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001332349), Brookdale Senior Living Inc. generated $3.19B in revenue (+2.2% YoY), -$262.7M in net income, and $16.5M in free cash flow against $5.95B in total assets and $4.22B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BKD last traded at $10.39 (+1.17% on volume of 5,487,423 shares), positioning the stock -5.80% below its 50-day simple moving average ($11.03) and -22.00% below its 200-day simple moving average ($13.32). Across its 52-week range of $8.02 to $17.09, BKD sits at the 26.1% percentile with a 14-day RSI of 46.0 (NEUTRAL RANGE) and an implied next-earnings move of ±7.1% ($9.65 to $11.13).
Why BKD Stock advanced +1.17% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (0% return on capital) under elevated 10-year interest-rate pressure.
The Roarable RQD score for BKD is 31 out of 100, graded E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid" (per the Roarable RQD rating). The five pillars are each scored out of 20:
Taken together, the composite points to a stock where the upside case depends on a turnaround in profitability and cash conversion that the current numbers do not yet show. Valuation tradeoffs are significant: EV/EBITDA of 34.6 (per market data) is high relative to the thin operating margin and near-zero ROIC, so a prospective investor is paying for improvement that has not yet arrived. The main upside driver would be sustained operating-margin and cash-flow improvement; the main downside is that the balance sheet has limited room to absorb further weakness.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $3194.1M | $13.5M | $-262.7M | N/A | $16.5M | $279.1M | $4215.0M |
| FY 2024 | $3125.5M | $46.5M | $-201.9M | N/A | $-35.1M | $308.9M | $4022.0M |
| FY 2023 | $3015.8M | $18.4M | $-189.0M | N/A | $162.9M | N/A | N/A |
Per the SEC financials, revenue rose across the three reported periods, but net income was negative in every period, and FY 2025 net income of $-262.7M was larger in magnitude than FY 2024's $-201.9M. Market data show a gross margin of 26.2%, operating margin of 0.4%, and net margin of -8.2%, with ROIC of 0.3%. The Altman Z-Score is 0.2 and the Piotroski F-Score is 4/9 (per the Roarable RQD rating), both weak readings. Debt of $4215.0M against cash of $279.1M (FY 2025) indicates a leveraged balance sheet, with Debt/Equity of 0.5 (per the Roarable RQD rating).
Per the recent news feed, the headlines reference the following items, all tagged YELLOW with MARKET WIRE impact:
The occupancy theme recurs across the items and the most recent negative headline points to slowing recovery, which is a risk watch item. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Brookdale Senior Living Inc. (BKD) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
PR Newswire report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
StockStory report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Brookdale Senior Living Inc. (BKD) market action, institutional positioning, and fundamental catalysts.
Welcome to the BKD (Brookdale Senior Living Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Hospital/Nursing Management. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on BKD, but look at what you are paying: current EV/EBITDA multiples with 26.2% gross margins. Unless Brookdale Senior Living Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on BKD, the market is fixating on short-term headline noise in Hospital/Nursing Management and ignoring the balance sheet and cash flow trajectory. At $10.27 (52-wk range $8.02 - $17.09), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).